Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report)’s stock price hit a new 52-week low on Thursday . The company traded as low as C$0.01 and last traded at C$0.02, with a volume of 31000 shares changing hands. The stock had previously closed at C$0.02.
Aequus Pharmaceuticals Trading Down 25.0 %
The company has a current ratio of 0.12, a quick ratio of 0.46 and a debt-to-equity ratio of 138.88. The business’s 50-day moving average is C$0.02 and its two-hundred day moving average is C$0.02. The firm has a market cap of C$1.99 million, a P/E ratio of -0.75 and a beta of 0.37.
Aequus Pharmaceuticals Company Profile
Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.
Read More
- Five stocks we like better than Aequus Pharmaceuticals
- Why Are Stock Sectors Important to Successful Investing?
- Hasbro’s Management Made All the Right Calls This Quarter
- Pros And Cons Of Monthly Dividend Stocks
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- Financial Services Stocks Investing
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
